We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

FGFR

Fibroblast growth factor receptor (FGFR) inhibitors act on FGFR1 to FGFR4, four receptor tyrosine kinases. FGFR signaling controls cell proliferation, migration and differentiation in development and angiogenesis. Amplifications, activating mutations and gene fusions of FGFR genes have been found in many tumor types. PD173074 was crystallized with the FGFR1 kinase domain in 1998, which showed how it occupies the adenosine triphosphate (ATP) pocket. Infigratinib and fexagratinib are FGFR-focused inhibitors used to study cells that depend on FGFR signaling. Nintedanib and pazopanib HCl inhibit FGFR together with vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Kinases outside the FGFR family are covered by sibling categories such as VEGFR and PDGFR.

2 Items

  • bFGF (119-126)
    Cat. No.
    A33464
    CAS No.
    152051-61-1

    bFGF (119-126)

    bFGF (119-126) is a peptide ligand that selectively targets FGFR1, disrupting the bFGF-FGFR1 interaction, which leads to inhibition of FGFR1 phosphorylation and subsequent downstream signaling pathways. This results in the promotion of apoptosis and suppression of cell proliferation, migration, angiogenesis, and metastasis. Additionally, when conjugated with a carrier, bFGF (119-126) enhances cellular uptake through FGFR-mediated endocytosis, serving as an effective FGFR-targeting agent. Its applications extend to research in various cancers, including lung cancer, breast cancer, glioblastoma, and ovarian cancer, particularly when combined with ultrasound and Doxorubicin to potentiate antitumor effects.

    In stock View Details
    5 mg
    $115.00
    10 mg
    $190.00
    All 2 sizes
  • Recifercept
    Cat. No.
    A33504
    CAS No.
    2226238-09-9

    Recifercept

    Synonyms: TA-46; sFGFR3

    Recifercept is a soluble recombinant fibroblast growth factor receptor 3 (FGFR3) designed to act as a decoy or ligand trap. By binding to fibroblast growth factors, it reduces their availability to mutant FGFR3 receptors, thereby modulating their activity. This reagent is particularly valuable for research focused on achondroplasia and related conditions involving FGFR3 mutations.

    In stock View Details
    0.5 mg
    $250.00
    1 mg
    $260.00
    All 4 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...